Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 2/20 | 0.70 |
| ▸ | CASP6 | P55212 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 8/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.55 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.55 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7258616 | 0.87 | CASP6 (0.53) | GFERCASP6MAPTKMT2AMEN1 | |
| SCHEMBL6756635 | 0.87 | GFER (0.66) | GFERCASP6MAPTKMT2AMEN1 | |
| SCHEMBL1483566 | 0.86 | MAPT (0.71) | GFERCASP6MAPTKMT2AMEN1 | |
| SCHEMBL14802425 | 0.84 | GFER (0.67) | GFERCASP6MAPTKMT2AMEN1 | |
| SCHEMBL10876210 | 0.83 | GFER (0.65) | GFERCASP6MAPTKMT2AMEN1 | |
| SCHEMBL1397464 | 0.82 | CHEK1 (0.69) | GFERMAPTKMT2AALDH1A1CHRNA7 | |
| SCHEMBL6152043 | 0.82 | GFER (1.00) | GFERCASP6MAPTKMT2AMEN1 | |
| SCHEMBL6152986 | 0.82 | GFER (1.00) | GFERCASP6MAPTKMT2AMEN1 | |
| SCHEMBL188503 | 0.82 | GFER (1.00) | GFERCASP6MAPTKMT2AMEN1 | |
| SCHEMBL4990421 | 0.82 | NAMPT (0.52) | GFERCASP6MAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007097697-A1 | THERAPEUTIC QUINOLINE COMPOUNDS THAT ARE 5HT1B MODULATORS | ASTRAZENECA AB (SE) | 2007-08-30 | — | — | WO | claimed |
| US-20050182050-A1 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | US | claimed |
| US-6812225-B2 | PYSCHOLOGICAL DISORDERS; ANTIDEPRESSANTS | ASTRAZENECA AB (SE) | 2004-11-02 | — | — | US | claimed |
| CN-1131222-C | Benzamide derivatives and their use as inhibitors of APOB-100 secretion | GLAXO GROUP LTD (GB) | 2003-12-17 | — | — | CN | claimed |
| WO-2003047575-A1 | THERAPEUTIC BENZAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-06-12 | — | — | WO | claimed |
| US-20030013708-A1 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | claimed |
| CN-1334808-A | Benzamide derivatives and their use as inhibitors of APOB-100 secretion | GLAXO GROUP LTD (GB) | 2002-02-06 | — | — | CN | claimed |
| EP-1135378-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-09-26 | — | — | EP | claimed |
| WO-2000032582-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-06-08 | — | — | WO | claimed |
| WO-2020183011-A1 | HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2020-09-17 | — | — | WO | disclosed |
| US-20080076759-A1 | Therapeutic Heterocyclic Compounds 507 | ASTRAZENECA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-7285662-B2 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| WO-2007097697-A1 | THERAPEUTIC QUINOLINE COMPOUNDS THAT ARE 5HT1B MODULATORS | ASTRAZENECA AB (SE) | 2007-08-30 | — | — | WO | disclosed |
| US-20060178372-A1 | Therapeutic quinoline compounds | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | US | disclosed |
| WO-2002055013-A2 | THERAPEUTIC CHROMONE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-18 | — | — | WO | disclosed |
| CN-1334808-A | Benzamide derivatives and their use as inhibitors of APOB-100 secretion | GLAXO GROUP LTD (GB) | 2002-02-06 | — | — | CN | disclosed |
| WO-2001097810-A2 | USE OF THERAPEUTIC BENZAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2001-12-27 | — | — | WO | disclosed |
| EP-1135378-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-09-26 | — | — | EP | disclosed |
| WO-2000032582-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-06-08 | — | — | WO | disclosed |
| CN-87102873-A | Phenylpiperazine anti-dysrhythmia agents and preparation method thereof | — | 1987-10-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076759-A1 | Therapeutic Heterocyclic Compounds 507 | HTR1A, HTR1B, HTR1D | GFER 4158/4885CASP6 2209/4885MAPT 698/4885 |
| US-20060178372-A1 | Therapeutic quinoline compounds | HTR1B, HTR3B, HTR1A | GFER 4571/4885CASP6 3287/4885MAPT 628/4885 |
| US-20050182050-A1 | Therapeutic heterocyclic compounds | HTR1B, HTR1D, HTR1A | GFER 4013/4885CASP6 2877/4885MAPT 653/4885 |
| US-20030013708-A1 | Therapeutic heterocyclic compounds | HTR1A, HTR1D, HTR1B | GFER 4158/4885CASP6 2951/4885MAPT 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.